title: New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline.
abstract: Mycobacterium tuberculosis develops spontaneous resistance mutants to virtually every drug in use. Courses of therapy select for these mutants and drug-resistant organisms emerge. The development of drug-resistant organisms has reached the point that drug resistance now threatens to undermine global success against tuberculosis (TB). New drugs are needed. The last new class of drugs specifically developed for treatment of TB was the rifamycins over 40 years ago. New funding sources and the development of product development partnerships have energized the TB drug development effort. There are now more TB drugs in development than at any time in the past. The first of these drugs to be developed and marketed was bedaquiline. Bedaquiline has an entirely novel mechanism of action and so should be active against otherwise highly resistant organisms. It acts on the transmembrane component of adenosine triphosphate synthase and acts by preventing electron transport. This raises the exciting possibility that bedaquiline may be active against less metabolically active organisms. Drug-drug interactions between rifamycins and the cytochrome P450-3A system will limit bedaquiline's utility and create complexity in treatment regimens. In clinical trials, treatment with bedaquiline added to a background multidrug-resistant TB regimen was associated with earlier culture conversion and higher cure rates, but there were unexplained excess deaths in the bedaquiline arms of these trials. Food and Drug Administration approved bedaquiline for the treatment of multidrug-resistant TB when an effective treatment regimen cannot otherwise be provided. They required a black box warning about excess deaths and require that a phase III trial be completed. A planned Phase III trial is being reorganized. While bedaquiline is an exciting drug and marks a dramatic moment in the history of TB treatment, its ultimate place in the anti-TB drug armamentarium is unclear pending the Phase III trial and the development of other new drugs that are in the pipeline.
authors.affiliation: Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, New York University School of Medicine, New York, NY, USA.
authors.forename: Eric
authors.initials: E
authors.lastname: Leibert
authors.affiliation: Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, New York University School of Medicine, New York, NY, USA.
authors.forename: Mauricio
authors.initials: M
authors.lastname: Danckers
authors.affiliation: Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, New York University School of Medicine, New York, NY, USA.
authors.forename: William N
authors.initials: WN
authors.lastname: Rom
keywords: Sirturo; bedaquiline; multidrug-resistant tuberculosis
references.citation: Int J Tuberc Lung Dis. 2001 Jan;5(1):1-3
references.pmid: 11263509
references.citation: Antimicrob Agents Chemother. 2006 Aug;50(8):2853-6
references.pmid: 16870785
references.citation: Antimicrob Agents Chemother. 2006 Nov;50(11):3543-7
references.pmid: 16954317
references.citation: Antimicrob Agents Chemother. 2014 May;58(5):2979-81
references.pmid: 24590481
references.citation: Am J Respir Crit Care Med. 2005 Apr 1;171(7):699-706
references.pmid: 15709048
references.citation: Am J Respir Crit Care Med. 1996 Apr;153(4 Pt 1):1377-84
references.pmid: 8616569
references.citation: Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62
references.pmid: 12588714
references.citation: Antimicrob Agents Chemother. 2014;58(1):574-6
references.pmid: 24126586
references.citation: J Bacteriol. 2010 Mar;192(6):1662-70
references.pmid: 20023019
references.citation: N Engl J Med. 2011 Oct 20;365(16):1471-81
references.pmid: 22010913
references.citation: Nat Rev Microbiol. 2005 Jan;3(1):70-80
references.pmid: 15608701
references.citation: Lancet. 2006 Nov 4;368(9547):1575-80
references.pmid: 17084757
references.citation: Am J Respir Crit Care Med. 2008 Feb 1;177(3):348-55
references.pmid: 17989346
references.citation: J Biol Chem. 2008 Sep 12;283(37):25273-25280
references.pmid: 18625705
references.citation: JAMA. 1995 Jan 18;273(3):220-6
references.pmid: 7807661
references.citation: Antimicrob Agents Chemother. 2012 Jun;56(6):3271-6
references.pmid: 22391540
references.citation: Antimicrob Agents Chemother. 2011 Dec;55(12):5485-92
references.pmid: 21930883
references.citation: Antimicrob Agents Chemother. 2007 Nov;51(11):4202-4
references.pmid: 17709466
references.citation: N Engl J Med. 1993 Sep 9;329(11):784-91
references.pmid: 8350889
references.citation: Lancet. 2006 Mar 18;367(9514):938-40
references.pmid: 16546542
references.citation: JAMA. 2013 Apr 3;309(13):1349-50
references.pmid: 23430122
references.citation: Antimicrob Agents Chemother. 2013 May;57(5):2199-203
references.pmid: 23459487
references.citation: Science. 2005 Jan 14;307(5707):223-7
references.pmid: 15591164
references.citation: N Engl J Med. 2011 Oct 20;365(16):1482-91
references.pmid: 22010914
references.citation: N Engl J Med. 2009 Jun 4;360(23):2466-7
references.pmid: 19494223
references.citation: Clin Pharmacokinet. 2001;40(5):327-41
references.pmid: 11432536
references.citation: Am J Respir Crit Care Med. 2009 Jan 1;179(1):2-3
references.pmid: 19098156
references.citation: Infect Disord Drug Targets. 2011 Apr;11(2):134-43
references.pmid: 21406051
references.citation: Antimicrob Agents Chemother. 2008 Aug;52(8):2831-5
references.pmid: 18505852
references.citation: Antimicrob Agents Chemother. 2009 Mar;53(3):1290-2
references.pmid: 19075053
references.citation: N Engl J Med. 2011 Oct 20;365(16):1492-501
references.pmid: 22010915
references.citation: N Engl J Med. 2009 Jun 4;360(23):2397-405
references.pmid: 19494215
references.citation: Am J Respir Crit Care Med. 1997 Mar;155(3):996-1003
references.pmid: 9117038
references.citation: Science. 2006 Mar 3;311(5765):1246-7
references.pmid: 16513969
references.citation: Nat Rev Microbiol. 2012 May 14;10(6):407-16
references.pmid: 22580364
references.citation: Am J Respir Crit Care Med. 2009 Jan 1;179(1):75-9
references.pmid: 18948422
references.citation: Am Rev Respir Dis. 1980 Jun;121(6):939-49
references.pmid: 6774638
references.citation: MMWR Recomm Rep. 2013 Oct 25;62(RR-09):1-12
references.pmid: 24157696